by Almas Shamim | Sep 7, 2015 | Blog
Tuberculosis – The Burden of Conditionality Almas Shamim The Indian Government, in its attempt to fight tuberculosis, has decided to make BDQ available through a conditional access program being funded mostly by a Janssen-USAID (United States Agency for...
by Almas Shamim | Jun 11, 2015 | Blog
Depending on Big Pharma for increased access Almas Shamim Gilead Sciences, a US based pharmaceutical company and the manufacturer of the new anti-Hepatitis C drugs, sofosbuvir and ledipasvir, announced a voluntary licensing (VL) agreement with seven Indian generic...
